Literature DB >> 3354755

Fibrosarcomatous change in dermatofibrosarcoma protuberans.

U Wrotnowski1, P H Cooper, B M Shmookler.   

Abstract

This report describes six patients with dermatofibrosarcoma protuberans (DFSP) that contained fibrosarcomatous areas (FS). The clinical signs and symptoms, ages of the patients, and anatomic distribution of the tumors were similar to those of uncomplicated DFSP. FS was concentrated in the subcutis in each case and comprised more than 50% of the tumor in four cases. The characteristic storiform cellular arrangement of DFSP was replaced by long, gently sweeping fascicles of spindle cells that intersected at various angles, forming the so-called herringbone pattern. Trapped fat cells, characteristic of DFSP when it infiltrates subcutaneous tissue, were absent in five of the six FS and only focally present in one. Two FS were grade 1; their cytologic features were similar to those of DFSP. Four FS were grade 2 and had cytologic atypia exceeding that of DFSP. There was a statistical difference between the mitotic rates of DFSP and FS. Five patients were alive and well at the time of last follow-up (median, 2 years), and one patient had an unexcised recurrence when last examined. Six similar cases from the literature are reviewed; in one of them, the FS metastasized.

Entities:  

Mesh:

Year:  1988        PMID: 3354755     DOI: 10.1097/00000478-198804000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

1.  COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans.

Authors:  J Wang; Y Morimitsu; S Okamoto; M Hisaoka; T Ishida; W Sheng; H Hashimoto
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas.

Authors:  Zoltan Szollosi; Beata Scholtz; Kristof Egervari; Zoltan Nemes
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

3.  CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

Authors:  Grant Eilers; Jeffrey T Czaplinski; Mark Mayeda; Nacef Bahri; Derrick Tao; Meijun Zhu; Jason L Hornick; Neal I Lindeman; Ewa Sicinska; Andrew J Wagner; Jonathan A Fletcher; Adrian Mariño-Enriquez
Journal:  Mol Cancer Ther       Date:  2015-04-07       Impact factor: 6.261

4.  Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases.

Authors:  Z Szollosi; Z Nemes
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

5.  Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy.

Authors:  Ryan C Fields; Meera Hameed; Li-Xuan Qin; Nicole Moraco; Xiaoyu Jia; Robert G Maki; Samuel Singer; Murray F Brennan
Journal:  Ann Surg Oncol       Date:  2010-09-16       Impact factor: 5.344

6.  Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not?

Authors:  Grace K Kim
Journal:  J Clin Aesthet Dermatol       Date:  2011-03

Review 7.  Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.

Authors:  Takeshi Iwasaki; Hidetaka Yamamoto; Yoshinao Oda
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

Review 8.  Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations.

Authors:  Cyril Fisher
Journal:  Virchows Arch       Date:  2009-04-28       Impact factor: 4.064

Review 9.  Current treatment options in dermatofibrosarcoma protuberans.

Authors:  Doreen Lemm; L-O Mügge; T Mentzel; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

Review 10.  Dermatofibrosarcoma protuberans: from translocation to targeted therapy.

Authors:  Jonathan Noujaim; Khin Thway; Cyril Fisher; Robin L Jones
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.